Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive platform trial of multiple therapies versus control in mild to moderate COVID-19
PACTR202006537901307Phase 3Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Jul 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of acetaminophen, lopinavir + ritonavir, hydroxychloroquine, nitazoxanide, ciclesonide and 5 more in coronavirus disease 2019 (COVID-19), sponsored by Drugs for Neglected Diseases initiative. Started Jul 2020; status: completed.
02
Drugs
acetaminophenlopinavir + ritonavirhydroxychloroquinenitazoxanideciclesonide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202006537901307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202006537901307.